A Single Arm, Open-label Study of MRD-Guided Zanubrutinib in Combination With Sonrotoclax in Adult Patients With Treatment Naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Latest Information Update: 14 Feb 2025
At a glance
- Drugs Sonrotoclax (Primary) ; Zanubrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
Most Recent Events
- 10 Dec 2024 Status changed from not yet recruiting to recruiting.
- 10 Dec 2024 Trial design presented at the 66th American Society of Hematology Annual Meeting and Exposition
- 18 Apr 2024 New trial record